Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study [PDF]
Joshua Choi +5 more
openalex +1 more source
A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis. [PDF]
Dermiki-Gkana F +3 more
europepmc +1 more source
Polymorphisms in the proprotein convertase subtilisin/kexin type 9 gene in clinically diagnosed patients with familial hypercholesterolemia. [PDF]
Costa ALDS +8 more
europepmc +1 more source
Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor [PDF]
Hagai Tavori +6 more
openalex +1 more source
Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors- Are We Doing Better? A Systematic Review on Treatment Disparity [PDF]
Chetana Singh +7 more
openalex +1 more source
Efficacy and safety of proprotein convertase subtilisin/kexin type 9 inhibitors for adults with familial hypercholesterolemia: A network meta-analysis. [PDF]
Ding W, Sun L, Shi Y, Tian L.
europepmc +1 more source
The chaperone GRP94 interacts with the proprotein convertase furin and regulates TGF-beta maturation in human primary M2 macrophages. [PDF]
Baverel V, Wang F, Garrido C, Kohli E.
europepmc +1 more source
Preventing SARS-CoV-2 infection using Fv-antibodies targeting the proprotein convertase (PPC) cleavage site [PDF]
Jaeyong Jung +7 more
openalex +1 more source
Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor) [PDF]
Ali Ben Djoudi Ouadda +17 more
openalex +1 more source

